Meda AB (publ) AGM bulletin
Business Wire - Wed May 06, 2:40PM CDT
Regulatory News:
MEDA: Invitation to Meda's Capital Markets Day on May 12, 2015
Business Wire - Tue Apr 28, 6:58AM CDT
Regulatory News:
MEDA: Meda's annual report is published
Business Wire - Wed Apr 08, 1:10AM CDT
Regulatory News:
MEDA AB (publ) Notice of Annual General Meeting 2015
Business Wire - Tue Mar 31, 8:19AM CDT
Regulatory News:
Meda's reports nomination committee's proposal for board composition
M2 - Wed Mar 18, 3:30AM CDT
Speciality pharmaceutical company Meda AB (STO:MEDAA) (Pink Sheets:MDABY) announced on Tuesday that the nomination committee of its board of directors has proposed the election of Kimberly Lein-Mathisen and Lillie Li Valeur as new board members.
MEDA: Nomination Committee's Proposal for Composition of the Board
Business Wire - Tue Mar 17, 8:45AM CDT
Regulatory News:
MEDA: Year-end Report, January-December 2014
Business Wire - Wed Feb 11, 1:21AM CST
Regulatory News:
MEDA: Invitation to Teleconference for Analysts, Investors and Journalists
Business Wire - Thu Feb 05, 5:45AM CST
Presentation of Meda's Year-End Results 2014
BioDelivery Sciences Acquires North American Marketing Authorizations for ONSOLIS from Meda
PR Newswire - Tue Jan 27, 6:00AM CST
BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that it has entered into an assignment and revenue sharing agreement with Meda AB (Meda) under which Meda will transfer the marketing authorizations for ONSOLIS® (fentanyl buccal soluble film, CII) for the United States and the right to seek marketing authorizations for ONSOLIS in Canada and Mexico, back to BDSI. BDSI originally licensed such rights to Meda in 2007, and ONSOLIS was approved by the U.S. Food and Drug Administration (FDA) and originally commercially launched in the United States in 2009.
BDSI: 8.64 (+0.15)
Meda reports change in number of shares and votes
M2 - Tue Dec 30, 6:20AM CST
Meda AB (STO:MEDA-A.ST) (Pink Sheets:MDABY), a specialty pharmaceutical company, on Tuesday announced an increase of shares and votes during December 2014 of a total of 33,224,306 shares of series A and the equivalent number of votes.
Change in Number of Shares and Votes in Meda
Business Wire - Tue Dec 30, 1:14AM CST
Regulatory News:
Meda and Cipla announce suing of Apotex to enforce Dymista patents
M2 - Thu Dec 04, 5:20AM CST
Meda AB (STO:MEDAA.ST), a specialty pharmaceutical company, and pharmaceutical company Cipla Ltd announced on Wednesday that they have sued Apotex Inc and Apotex Corp in Federal District Court in Delaware to enforce the Orange-Book listed patents covering Dymista (azelastine HCl/fluticasone propionate) Nasal Spray.
Meda AB (publ) Extraordinary General Meeting Bulletin
Business Wire - Thu Nov 06, 7:56AM CST
Regulatory News:
Meda announces change in number of shares and votes
M2 - Fri Oct 31, 5:09AM CDT
Speciality pharmaceutical company Meda AB (STO:MEDAA.ST) announced today that as a part of the agreed purchase price for Rottapharm S.p.A., it has completed an issue of 30,000,000 series A shares in favour of Rottapharm's previous owners, Fidim S.r.l.
Meda announces appointment of nomination committee members for AGM 2015
M2 - Wed Oct 15, 6:49AM CDT
Specialty pharmaceutical company Meda AB (STO:MEDAA.ST) announced on Wednesday that the members of its nomination committee for the Annual General Meeting 2015 are Bert Ake Eriksson, committee chairman; Stena Sessan of Rederi AB; Sigieri Diaz Pallavicini of Fidim S.r.l; Evert Carlsson of Swedbank Robur Funds; Lars Backsell of B&E Participation/Flerie Invest; and Martin Svalstedt, Meda's chairman of the board of directors.